Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, Australia; New South Wales Health Pathology, Sydney, Australia.
Department of Pharmacy, Northern Sydney Local Health District, Sydney, Australia.
Ann Allergy Asthma Immunol. 2019 Nov;123(5):468-475. doi: 10.1016/j.anai.2019.08.005. Epub 2019 Aug 13.
Nonprescription of penicillin-containing antibiotics in patients diagnosed with penicillin allergy is associated with morbidity and mortality. Adverse reactions to penicillins comprise type A and B reactions.
To assess the feasibility of penicillin allergy evaluation without penicillin skin testing (PST) for adult patients with type B reactions and the health and economic benefits of this process.
Inpatients at an Australian tertiary hospital between April 1, 2017, and April 30, 2018, with a diagnosis of type B penicillin allergy, requiring a penicillin-containing antibiotic for treatment, were included. All patients underwent clinical history review, PST, and drug provocation testing (DPT).
Seventy-one patients were enrolled. Sixty-three reported a history of type B or unknown adverse reactions. No patients had a history of anaphylaxis requiring intubation or epinephrine within the last 10 years or a history suggesting Gell and Coombs type 2, 3, or 4 (severe) hypersensitivity reaction. Seven did not complete DPT because the treating team used a β-lactam antibiotic other than amoxicillin. Fifty-four of 56 remaining patients (96%) completed 3-day DPT to amoxicillin with no adverse reaction. Two experienced mild cutaneous reactions. Penicillin allergy evaluation was significantly associated with reduced length of stay, reduced hospital expenditure on bed and second-line antibiotics, and reduced readmission rates.
Penicillin allergy evaluation with DPT without PST may be feasible for all adult patients with a reported history of type B reactions to penicillins who do not have a history of anaphylaxis within the last 10 years or a type 2, 3, or 4 (severe) hypersensitivity reaction.
对诊断为青霉素过敏的患者开具不含青霉素的抗生素可能会导致发病率和死亡率升高。青霉素类药物不良反应包括 A 型和 B 型反应。
评估不进行青霉素皮试(PST)而对 B 型反应的成年患者进行青霉素过敏评估的可行性,以及该过程的健康和经济效益。
2017 年 4 月 1 日至 2018 年 4 月 30 日,纳入在澳大利亚一家三级医院住院且诊断为 B 型青霉素过敏、需要使用含青霉素抗生素治疗的患者。所有患者均进行了临床病史回顾、PST 和药物激发试验(DPT)。
共纳入 71 例患者。63 例报告有 B 型或未知不良药物反应史。在过去 10 年内,没有患者有因过敏反应需要插管或使用肾上腺素的病史,也没有病史提示存在 2、3 或 4 型(严重)Gell 和 Coombs 型超敏反应。有 7 例患者因治疗团队使用了非阿莫西林的β-内酰胺类抗生素而未完成 DPT。在其余 56 例患者中,54 例(96%)完成了 3 天阿莫西林 DPT,且无不良反应。2 例患者出现轻度皮肤反应。青霉素过敏评估与住院时间缩短、床位和二线抗生素支出减少以及再入院率降低显著相关。
对于过去 10 年内无过敏反应史且无 2、3 或 4 型(严重)超敏反应史的报告有 B 型青霉素类药物不良反应史的所有成年患者,不进行 PST 而进行 DPT 可能是可行的。